Validation in 31 pediatric SMA patients (types 1–3 and presymptomatic) revealed significantly decreased cathepsin D levels in treatment-responsive patients aged ≥2 months at therapy initiation, with this decline being most pronounced in responders [142]. The gene discussed is CTSD; the disease is proximal spinal muscular atrophy.